APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 323 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,934,206 | -14.3% | 1,023,507 | +105.2% | 0.12% | -22.9% |
| Q2 2023 | $45,432,481 | -7.3% | 498,710 | -32.9% | 0.16% | -9.8% |
| Q1 2023 | $49,024,506 | +130176.9% | 743,246 | +2.1% | 0.17% | +27.9% |
| Q4 2022 | $37,631 | -100.0% | 727,729 | -40.6% | 0.14% | -57.6% |
| Q3 2022 | $83,690,000 | +109.5% | 1,225,336 | +38.7% | 0.32% | +116.9% |
| Q2 2022 | $39,949,000 | +53.3% | 883,438 | +72.2% | 0.15% | +105.6% |
| Q1 2022 | $26,067,000 | +719.5% | 513,027 | +662.5% | 0.07% | +700.0% |
| Q4 2021 | $3,181,000 | -78.7% | 67,282 | -71.5% | 0.01% | -82.4% |
| Q2 2021 | $14,901,000 | +2904.2% | 235,775 | +1334.8% | 0.05% | +1600.0% |
| Q3 2020 | $496,000 | -15.4% | 16,433 | -32.4% | 0.00% | -25.0% |
| Q3 2019 | $586,000 | -90.3% | 24,312 | -92.1% | 0.00% | -93.0% |
| Q1 2019 | $6,025,000 | – | 308,992 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 1,526,122 | $29,759,000 | 24.10% |
| Cormorant Asset Management, LP | 3,600,000 | $70,200,000 | 4.74% |
| SECTORAL ASSET MANAGEMENT INC | 1,727,829 | $33,693,000 | 4.05% |
| Hillhouse Capital Management | 2,098,581 | $40,922,000 | 1.71% |
| HHLR ADVISORS, LTD. | 2,579,708 | $50,304,000 | 1.40% |
| CLOUGH CAPITAL PARTNERS L P | 589,734 | $11,500,000 | 1.01% |
| Vivo Capital, LLC | 383,538 | $7,479,000 | 0.75% |
| Opaleye Management Inc. | 115,000 | $2,243,000 | 0.62% |
| Virtus ETF Advisers LLC | 14,338 | $280,000 | 0.60% |
| Eversept Partners, LP | 104,349 | $2,034,806 | 0.59% |